semaglutide week 2 VisualAbstract: 2.4 mg once a decreases bodyweight in overweight or obese patients with type diabetes Week 2 : r/Semaglutide

Please keep out of reach of children

According to the Phase 3b, double-blind, placebo-controlled STRIDE study, Ozempic (1 mg) resulted in a superior and clinically meaningful improvement of 13% in maximum walking distance and a mean treatment difference of 39.9 meters on a steep incline compared to placebo at week 52 in adults with T2DM and PAD. If approved, Ozempic will be the only GLP-1 receptor agonist indicated for the treatment of PAD in patients with T2DM

5,6,8 In a trial of non-diabetic adults with obesity, 21 all patients received a lifestyle intervention and were randomized to receive either weekly injections of semaglutide the drug in Ozempic and Wegovy or placebo

111(Pt 2), 237247

Our NAD+ Support Add-On is a 100ml IV given right after your NAD+ treatment